IL-2 immunotherapy in chronically SIV-infected Rhesus Macaques

BACKGROUND: Despite inducing a sustained increase in CD4+ T cell counts, intermittent recombinant IL-2 (rIL-2) therapy did not confer a better clinical outcome in HIV-infected patients enrolled in large phase III clinical trials ESPRIT and SILCAAT. Several hypotheses were evoked to explain these dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Garibal, Julie, Laforge, Mireille, Silvestre, Ricardo, Mouhamad, Shahul, Campillo-Gimenez, Laure, Lévy, Yves, Estaquier, Jérôme
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3499432/
https://www.ncbi.nlm.nih.gov/pubmed/23021024
http://dx.doi.org/10.1186/1743-422X-9-220

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3499432/
https://www.ncbi.nlm.nih.gov/pubmed/23021024
http://dx.doi.org/10.1186/1743-422X-9-220

Ejemplares similares